Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolised liposomal cyclosporin A for prevention of bronchiolitis obliterans after lung transplantation
ISRCTN66069132Phase 3Completed
- Sponsor
- PARI Pharma
- Start
- Dec 2009
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, double-blind trial in Bronchiolitis Obliterans Syndrome (BOS) comparing Aerosolised liposomal cyclosporin A plus standard of care with Aerosolised placebo plus standard of care (2 arms). Primary endpoints: BOS-free survival and Bronchiolitis obliterans syndrome occurrence. Started Dec 2009; status: completed.
02
Drugs
cyclosporine
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on ISRCTN66069132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66069132.